Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab-based first-line treatment study in unresectable or metastatic urothelial carcinoma
MOH_2018-03-19_002057Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab and ipilimumab in transitional cell carcinoma (TCC) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Overall survival and Progression-free survival. Started Jan 2018; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on MOH_2018-03-19_002057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-03-19_002057.